Back to List View Graph View

Metabolic dysfunction–associated steatotic liver disease

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), is a chronic liver disease defined by hepatic fat accumulation (steatosis) arising in the setting of metabolic dysfunction—such as obesity, insulin resistance, type 2 diabetes, hypertension, and dyslipidemia—and may coexist with other causes of liver injury; moderate alcohol intake is classified separately as MetALD.

Where the papers sit

27 papers from the last 6 months study metabolic dysfunction–associated steatotic liver disease directly · updated from PubMed 15 Nov 2026

  • Hepatic Metabolism and Inflammation

    Mechanistic work is shifting toward the interaction of lipid metabolism, mitochondrial function and inflammatory signaling in MASLD. Pleiotrophin deletion, AIBP activity, STAT3 inhibition by linderane and Akt-linked compounds identify pathway-specific routes to reduce steatosis and inflammation. Age, sex, vitamin D status and genetic variation recur as modifiers of these responses. Multi-omics and proteomic signatures are extending the field toward prevention and systemic cardiovascular–kidney risk prediction, but clinical translation remains unresolved.

    11 papers · 40.7%

  • MASLD Fibrosis Assessment

    Risk stratification is moving toward combining noninvasive tests, quantitative ultrasound, histology, imaging and clinical risk models. Fibrosis progression, decompensation and mortality remain the central endpoints, with metabolic factors helping identify higher-risk patients. Cellular studies add fibroblast activation protein and fibrosis-associated endothelial cells as candidate mechanistic markers. Two-step care pathways and deep-learning analysis point toward earlier referral, although validation across settings remains open.

    10 papers · 37%

  • Gut–Liver Axis Therapies

    Gut barrier integrity, intestinal signaling and hepatic FXR activity are being treated as linked therapeutic targets. Pectic polysaccharides and quaternized chitosan–whey protein materials aim to restore gut–liver homeostasis while altering lipid metabolism. FXR mRNA delivered by lipid nanoparticles may improve response to low-dose FXR agonists and limit systemic exposure. The common direction is toward combined microbiome, barrier and liver-directed treatment rather than isolated hepatic therapy.

    3 papers · 11.1%

  • Diabetes and Liver Disease

    Type 2 diabetes, obesity and liver disease are being considered together in both clinical management and patient experience. Imeglimin is being evaluated for efficacy and safety in patients with MASLD and type 2 diabetes, while gamma-glutamyltransferase, hemoglobin A1c and body composition frame metabolic risk. Social determinants and patient-reported concerns broaden the question beyond glycemic control. The cluster supports integrated diabetes–liver care but does not establish a clear therapeutic direction.

    3 papers · 11.1%

PARADIGM SHIFT

MASLD is not a single biologically coherent disease category, and its clinical boundaries do not reliably represent underlying biology

The proteomic comparison of MASLD, MetALD, and non-steatotic controls found distinct plasma signatures for MASLD versus controls but no proteomic distinction between MASLD and MetALD as currently defined 42809338Sep, while the multi-omics analysis of genetically defined MASLD subtypes identified separate forms involving hepatic lipid retention, hepatic lipid synthesis, and systemic lipid metabolism, each with different risks for extrahepatic diseases 42580475Aug. Together, these findings challenge the assumption that the current clinical label identifies one uniform disease with biologically meaningful boundaries. MASLD would instead need to be treated as a heterogeneous set of molecular phenotypes, with disease classification and risk prediction potentially organized around biological subtypes rather than the present category definitions.

Papers

The 27 papers from the last 6 months that study metabolic dysfunction–associated steatotic liver disease directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Hepatic Metabolism and Inflammation (11)
  1. Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality. Medical science monitor : international medical journal of experimental and clinical research · 17 Oct 2026 PMID 42888835
  2. Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD. Liver international : official journal of the International Association for the Study of the Liver · 29 Sept 2026 PMID 42809338
  3. Regulation of hepatic mitochondrial function by AIBP mitigates MASLD development. Metabolism: clinical and experimental · 10 Sept 2026 PMID 42722289
  4. Deciphering the polypharmacology of a traditional Chinese formula for MASLD: Network proximity to identifying Akt-modulating active ingredients. Journal of ethnopharmacology · 26 Aug 2026 PMID 42648411
  5. Unveiling the role of age in MASLD development and biological process activation: Implications for translational research. Journal of physiology and biochemistry · 22 Aug 2026 PMID 42631767
  6. Deletion of Pleiotrophin protects against high-fat diet-induced liver metabolic disease, independently of the sexual dimorphism in dietary response. Molecular biomedicine · 20 Aug 2026 PMID 42622926
  7. Multi-omics dissection of MASLD reveals divergent pathways to systemic diseases and targets for prevention. Metabolism: clinical and experimental · 11 Aug 2026 PMID 42580475
  8. Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD. Journal of gastroenterology and hepatology · 4 Aug 2026 PMID 42548272
  9. Sex-divergent metabolic pathways in the association between vitamin D status and metabolic-associated fatty liver disease. Medicine · 25 Jul 2026 PMID 42499071
  10. Linderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD. Journal of ethnopharmacology · 13 Jun 2026 PMID 42288160
  11. Clinical utility of a novel index for predicting metabolic dysfunction-associated steatotic liver disease risk in children. European journal of pediatrics · 1 Jun 2026 PMID 42223658
MASLD Fibrosis Assessment (10)
  1. Fasting glucose-to-HDL cholesterol ratio and risk of MASLD in nonobese Chinese adults: A retrospective cohort study. Medicine · 6 Nov 2026 PMID 42994841
  2. Mapping vascular plasticity during fibrogenesis identifies fibrosis-associated endothelial cells in early-stage liver disease. JCI insight · 1 Sept 2026 PMID 42678740
  3. Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort. Hepatology international · 27 Aug 2026 PMID 42658470
  4. Quantitative Ultrasound-Based Compression and Shear Wave Attenuation for Metabolic Dysfunction-Associated Steatotic Liver Disease Grading. Ultrasound in medicine & biology · 21 Aug 2026 PMID 42629303
  5. Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics. Cell genomics · 20 Aug 2026 PMID 42624116
  6. Metabolic risk and metabolic dysfunction-associated steatotic liver disease and steatohepatitis in cognitive decline: A retrospective cohort study. PloS one · 9 Jul 2026 PMID 42424274
  7. Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification. Hepatology communications · 19 Jun 2026 PMID 42319114
  8. High performance deep-learning model for the diagnosis of auto-immune hepatitis based on histological whole slide images. Virchows Archiv : an international journal of pathology · 16 Jun 2026 PMID 42301307
  9. Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study. Hepatology communications · 11 Jun 2026 PMID 42275588
  10. Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208
Gut–Liver Axis Therapies (3)
  1. Hepatic delivery of FXR mRNA via lipid nanoparticles enhances the efficacy of a low-dose FXR agonist in the treatment of MASLD. Nanomedicine : nanotechnology, biology, and medicine · 3 Oct 2026 PMID 42829150
  2. Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis. Carbohydrate polymers · 23 Jul 2026 PMID 42493082
  3. Biocompatible Quaternized Chitosan-Whey Protein Nanofibrous Porous Microspheres for Multi-Functional Synergistic Regulation of the Gut-Liver Axis in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Advanced materials (Deerfield Beach, Fla.) · 23 Jul 2026 PMID 42489146
Diabetes and Liver Disease (3)
  1. Efficacy and safety of imeglimin hydrochloride for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: Single-center, single-arm phase 2 (IMELD study). Medicine · 17 Oct 2026 PMID 42888537
  2. Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study. JMIR formative research · 15 Jun 2026 PMID 42296541
  3. Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast. Advances in therapy · 6 Jun 2026 PMID 42250074

By study type

Clinical trials (1)
  1. Efficacy and safety of imeglimin hydrochloride for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: Single-center, single-arm phase 2 (IMELD study). Medicine · 17 Oct 2026 PMID 42888537
Observational studies and case reports (6)
  1. Fasting glucose-to-HDL cholesterol ratio and risk of MASLD in nonobese Chinese adults: A retrospective cohort study. Medicine · 6 Nov 2026 PMID 42994841
  2. Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD. Liver international : official journal of the International Association for the Study of the Liver · 29 Sept 2026 PMID 42809338
  3. Sex-divergent metabolic pathways in the association between vitamin D status and metabolic-associated fatty liver disease. Medicine · 25 Jul 2026 PMID 42499071
  4. Metabolic risk and metabolic dysfunction-associated steatotic liver disease and steatohepatitis in cognitive decline: A retrospective cohort study. PloS one · 9 Jul 2026 PMID 42424274
  5. Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study. JMIR formative research · 15 Jun 2026 PMID 42296541
  6. Clinical utility of a novel index for predicting metabolic dysfunction-associated steatotic liver disease risk in children. European journal of pediatrics · 1 Jun 2026 PMID 42223658
Human data, design not indexed (4)
  1. Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality. Medical science monitor : international medical journal of experimental and clinical research · 17 Oct 2026 PMID 42888835
  2. Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD. Journal of gastroenterology and hepatology · 4 Aug 2026 PMID 42548272
  3. Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification. Hepatology communications · 19 Jun 2026 PMID 42319114
  4. Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study. Hepatology communications · 11 Jun 2026 PMID 42275588
Preclinical: animal, cell and lab studies (5)
  1. Mapping vascular plasticity during fibrogenesis identifies fibrosis-associated endothelial cells in early-stage liver disease. JCI insight · 1 Sept 2026 PMID 42678740
  2. Unveiling the role of age in MASLD development and biological process activation: Implications for translational research. Journal of physiology and biochemistry · 22 Aug 2026 PMID 42631767
  3. Deletion of Pleiotrophin protects against high-fat diet-induced liver metabolic disease, independently of the sexual dimorphism in dietary response. Molecular biomedicine · 20 Aug 2026 PMID 42622926
  4. Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis. Carbohydrate polymers · 23 Jul 2026 PMID 42493082
  5. Linderane, a furanosesquiterpene from Lindera aggregata, targets STAT3 to improve metabolic and inflammatory features of MASLD. Journal of ethnopharmacology · 13 Jun 2026 PMID 42288160
Unclassified: not yet indexed with MeSH (11)
  1. Hepatic delivery of FXR mRNA via lipid nanoparticles enhances the efficacy of a low-dose FXR agonist in the treatment of MASLD. Nanomedicine : nanotechnology, biology, and medicine · 3 Oct 2026 PMID 42829150
  2. Regulation of hepatic mitochondrial function by AIBP mitigates MASLD development. Metabolism: clinical and experimental · 10 Sept 2026 PMID 42722289
  3. Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort. Hepatology international · 27 Aug 2026 PMID 42658470
  4. Deciphering the polypharmacology of a traditional Chinese formula for MASLD: Network proximity to identifying Akt-modulating active ingredients. Journal of ethnopharmacology · 26 Aug 2026 PMID 42648411
  5. Quantitative Ultrasound-Based Compression and Shear Wave Attenuation for Metabolic Dysfunction-Associated Steatotic Liver Disease Grading. Ultrasound in medicine & biology · 21 Aug 2026 PMID 42629303
  6. Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics. Cell genomics · 20 Aug 2026 PMID 42624116
  7. Multi-omics dissection of MASLD reveals divergent pathways to systemic diseases and targets for prevention. Metabolism: clinical and experimental · 11 Aug 2026 PMID 42580475
  8. Biocompatible Quaternized Chitosan-Whey Protein Nanofibrous Porous Microspheres for Multi-Functional Synergistic Regulation of the Gut-Liver Axis in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Advanced materials (Deerfield Beach, Fla.) · 23 Jul 2026 PMID 42489146
  9. High performance deep-learning model for the diagnosis of auto-immune hepatitis based on histological whole slide images. Virchows Archiv : an international journal of pathology · 16 Jun 2026 PMID 42301307
  10. Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast. Advances in therapy · 6 Jun 2026 PMID 42250074
  11. Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208